Rhevera Medical Marks 2,000 Patients Treated with the DETOUR® System for Complex Peripheral Arterial Disease
Milestone coincides with the company’s new brand identity and more than 260 patients enrolled in the PTAB1 real-world
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
Rhevera Medical (formerly Endologix Holdings, LLC) today announced that more than 2,000 patients have now been treated with percutaneous transmural arterial bypass (PTAB) using the DETOUR® System, a minimally invasive therapy for patients with long, complex superficial femoral artery disease. The total includes patients treated in the DETOUR1 and DETOUR2 clinical studies and patients treated since the system’s commercial launch in July 2023.
The DETOUR System, composed of the ENDOCROSS™ device and TORUS™ stent grafts, enables physicians to percutaneously bypass lesions in the superficial femoral artery (SFA) by routing stents through the femoral vein to restore blood flow to the leg. PTAB with the DETOUR System offers lasting outcomes similar to open surgical bypass with synthetic graft, giving patients with complex peripheral arterial disease (PAD) a minimally invasive treatment option.
“Patients with long-segment disease often have limited treatment options, and the disease itself can threaten their mobility and independence,” said Dr. Prakash Krishnan, MD, Icahn School of Medicine at Mount Sinai, who performed the 2,000th procedure. “Reaching 2,000 patients shows how much physician experience with PTAB has grown, particularly in cases where conventional endovascular approaches and open surgery may not fully address a patient’s clinical needs.”
This milestone comes on the heels of additional progress with the PTAB1 study, a postmarket, multi-center, real-world registry evaluating the safety and clinical performance of the DETOUR System, which has now enrolled more than 260 patients and is tracking outcomes in patients with complex, long-segment PAD.
“The DETOUR System creates a new path for blood flow rather than working within a diseased artery, allowing physicians to treat long, complex lesions percutaneously,” said John Liddicoat, M.D., President and Chief Executive Officer of Rhevera Medical. “Reaching 2,000 patients as we introduce our new brand identity reflects what Rhevera stands for: addressing the complex cases conventional approaches leave unresolved.”
In October 2026, Endologix Holdings, LLC announced Rhevera Medical as its new corporate brand. Endologix LLC remains the legal manufacturer of the company’s products. To learn more, visit rheveramed.com.
About the DETOUR System
PTAB with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral artery, by using stents routed through the femoral vein via a transmural passage, to restore blood flow to the leg. This approach offers a treatment option for patients with long lesions (20cm-46cm in length), those that have already undergone failed endovascular procedures, or those that may be sub-optimal candidates for open surgical bypass.
About Rhevera Medical Holdings, LLC
Rhevera Medical Holdings, LLC (formerly Endologix Holdings, LLC) is a California-based, global medical device company dedicated to preserving and restoring the blood flow patients depend on. The Rhevera family of companies is focused on differentiated therapies for the interventional treatment of vascular disease, with an emphasis on the complex cases conventional approaches leave unresolved. Rhevera Medical is the parent company of Endologix LLC, which will continue to serve as the legal manufacturer of the company’s commercial products, including the DETOUR® System, the ALTO® Abdominal Stent Graft System, the AFX®2 Endovascular AAA System, and the Pounce™ Thrombectomy System. These products are designed to preserve and restore flow across a range of vascular diseases, from peripheral arterial disease to abdominal aortic aneurysms.
Rhevera is a portfolio company of investment funds managed by Deerfield Management, a firm committed to advancing healthcare through investment, intelligence, and philanthropy. The company has offices and manufacturing sites in Santa Rosa and Irvine, California. To learn more about Rhevera Medical, please visit https://rheveramed.com.
Important Safety Information
INDICATIONS: The DETOUR System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200mm to 460mm in length with chronic total occlusions (100mm to 425mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR System, or any of its components, is not for use in the coronary and cerebral vasculature.
CONTRAINDICATIONS: The DETOUR System is contraindicated in patients with: (1) a distal common femoral artery (CFA) <7 mm in diameter; (2) increased risk of deep vein thrombosis (DVT), such as patients with a recent history of DVT, thrombophilia, and disseminated malignancy; (3) untreated flow-limiting aortoiliac occlusive disease; (4) lack of patent single vessel tibial runoff to ankle; (5) known coagulopathy, bleeding diathesis, or thrombocytopenia that cannot be medically managed; (6) known hypersensitivities, allergies or contraindications to: Nitinol; PTFE; aspirin; heparin; antiplatelet; anticoagulant or thrombolytic therapy; or contrast media that cannot otherwise be medically managed.
WARNINGS: In the DETOUR2 Clinical Study, venous event rates were higher in females than males. This should be considered in patient selection and post-procedure management. Inadvertent, partial, or failed deployment or migration of the stent graft may require surgical intervention.
PRECAUTIONS: (1) Consider recent DVT history in the target limb in case planning and post-procedure anticoagulation as use of the DETOUR System uses a bypass conduit within the femoral vein. (2) Antiplatelet medication should be initiated prior to placement of the stent graft. (3) Effective dual antiplatelet therapy should be maintained following the procedure at a dosage deemed appropriate by the physician. (4) A knee prosthesis may prevent successful and accurate ENDOCROSS Device needle deployment.
POSSIBLE ADVERSE EVENTS related to percutaneous transmural arterial bypass with the DETOUR System include: access vessel occlusion; amputation; aneurysm or pseudoaneurysm; arteriovenous fistula; bleeding complications; death; device or deployment malfunction/failure; drug reactions to antiplatelet agents or contrast medium; edema; embolism; fever in absence of infection; hemorrhage or hematoma; hypotension/hypertension; infection; malposition; migration; myocardial infarction; pain; peripheral ischemia; renal insufficiency or failure secondary to contrast medium; shock; side branch vessel occlusion; stenosis or occlusion; stroke or transient ischemic attack; thrombosis; vessel wall trauma; vessel spasm; venous flow disruption; worsening claudication.
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
ATTENTION: See Instructions for Use for a complete listing of Indications, Contraindications, Warnings, Precautions, and Adverse Events.
NOTE: Not all product components are available in every country. Please consult with your Rhevera representative to confirm product availability. Rhevera Medical is the parent company of Endologix LLC. Endologix LLC is the manufacturer of the company’s products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117866769/en/
Media gallery
